
Medical Device R&D and Manufacturer

As the 2024 financial reports are gradually released, the performance of pharmaceutical giants has once again become the focus of industry attention.This year, the "King of Drugs" K DrugGenerated Revenue of $29.482 Billion,In the face of strong opponents「Semaglutide」Faced with the ultimate life-saving option, Cilta-cel,Pluvicto Wait for newEmerging products are also constantly rising and breaking through. However, at the same time, with the approaching patent cliff, MNCs are resorting to various strategies, competing to lay out their future plans and seeking new points of performance growth.
This article will highlight the latest developments of pharmaceutical giants based on the 2024 performance of 13 TOP MNCs, for readers' reference only. Scan the QR code at the end of the article to download the 2024 financial reports PPT of major MNCs.
Overview of 2024 Performance of 13 Top MNCs (Unit: Billion USD)

Johnson & Johnson:Daratumumab Revenue Breaks $10 Billion for the First Time

Merck: K Drug Remains the Pillar, Revenue of $29.5 Billion
In 2024, Merck's global revenue reached $64.2 billion, representing a 7% year-over-year increase. Of this, pharmaceutical business revenue was $57.4 billion, also reflecting a 7% growth. Merck anticipates that its revenue for 2025 will range between $64.1 billion and $65.6 billion.

In terms of product revenue,The pillar remains the star product PD-1 inhibitor Keytruda (Pembrolizumab), with sales increasing by 18% to $29.5 billion, contributing nearly 46% of Merck's revenue.However, another leading product, the HPV vaccine Gardasil/Gardasil 9, performed poorly, generating only $8.583 billion in revenue last year, a year-on-year decrease of 3%. Merck stated,This is mainly due to weak demand for HPV vaccines in the Chinese market.. In order to deplete inventory, Merck willSuspension of Quadrivalent HPV Vaccine Supply to ChinaGardasil,The nine-valent HPV vaccine continues to be shipped.
Among other products, those with relatively fast growth also includeHIF-2α Inhibitor Welireg (Belzutifan), with sales of $509 million, increasing by 133%. Approved for marketing in 2024(United States, European Union)ThePulmonary Arterial Hypertension Drug Winrevair (Sotatercept)Sales reached $419 million. In addition, the drug for preventing cytomegalovirus infectionPrevymis (Letermovir)Sales increased by 30% to USD 785 million,15-Valent Pneumococcal Vaccine VaxneuvanceSales increased by 22% to USD 808 million.
In 2023, Pfizer's total revenue declined due to fluctuations in the income from COVID-19 products.In 2024, Pfizer's revenue returned to growth, with a total annual income of $63.6 billion, representing a 7% year-over-year increase.; Excluding COVID products, growth was 12%. Pfizer forecasts revenue between $61 billion and $64 billion for 2025 and expressed confidence in its earnings report of returning to pre-pandemic operating profit margins in the coming years.

From the perspective of business segments,Primary Care Product Revenue: $30.135 Billion, Down 2% Year-over-YearAmong them, the anticoagulant drug Eliquis (apixaban) generated revenue of $7.366 billion (+9%), while the pneumonia vaccine Prevnar family brought in $6.411 billion (-1%).
Specialty Care revenue reached $16.652 billion, representing an 11% year-over-year increase.Among them, the revenue of Vyndaqel family, a rare disease drug containing chlorbenzazole, reached 5.451 billion US dollars, increasing by 64% year-on-year. The revenue of JAK inhibitor Xeljanz (tofacitinib) was 1.168 billion US dollars, decreasing by 31% year-on-year.
Oncology Business Revenue $15.612 Billion, Up 25% Year-on-YearAmong them, the revenue of CDK 4/6 inhibitor Ibrance (Palbociclib) was $4.367 billion, a year-on-year decrease of 8%. The revenue of androgen receptor inhibitor Xtandi (Enzalutamide) was $2.039 billion, a year-on-year increase of 23%. The revenue of PARP inhibitor Talzenna (Talazoparib) was $117 million, a year-on-year increase of 83%.
Novartis: China Market Becomes Key Driver
Novartis' Ace Product Entresto(Sacubitril Valsartan)Since its launch, sales have continued to grow, reaching $7.822 billion in 2024, a year-on-year increase of 31%.
Leqvio isWorld's First siRNA Ultra-Long-Acting Lipid-Lowering Drug, its sales achieved rapid growth in 2024, reaching 754 million US dollars, a year-on-year increase of 114%.

AbbVie: Surge in R&D Investment, Strong Performance in Autoimmune Drugs
In 2024, AbbVieTotal annual revenue of $56.334 billion,Investment in R&D fields at the same timeA significant year-on-year increase of 66.7%Reached 12.791 billion US dollars.
AbbVie's 3 Key Drugs in the Autoimmune Field Show Outstanding Performance:Skyrizi(Lisocabtagene Maraleucel)、Rinvoq(Upadacitinib)AndHumira(Adalimumab), respectively achievedSales of $11.718 billion, $5.971 billion, and $8.993 billion. Among them, SkyriziFollowing Humira to become the next$10 Billion Molecule。
From 2025 to 2026, AbbVie will achieve multiple regulatory approvals, submissions of marketing applications, and clinical data readouts for new drugs/indications. In its financial report, AbbVie reiterated that it expects to maintain a high single-digit compound annual revenue growth rate before 2029 and raised its forecast for the combined sales of Skyrizi and Rinvoq.More than 310 billion US dollars, while updating the outlook for the aesthetics business, with an expected high single-digit compound annual revenue growth rate from 2025 to 2029.

Sanofi: Dupixent Crowned as the "King of Autoimmune Drugs"
In 2024,SanofiAnnual revenue of 41.081 billion euros(Approximately USD 44.561 billion), an increase of 11.3% year-on-year. The total R&D investment for the year was 7.394 billion euros.(Approximately USD 8.02 billion), an increase of 14.6% year-on-year.
It is worth mentioning that the flagship product Dupixent(Dupilumab)Global sales reached in 2024$14.179 billion, a year-on-year increase of 23.1%, becomingNew Generation Autoimmunity「Medicine King」。In addition, Sanofi has a diversified pipeline of projects, such as Rilzabrutinib for immune thrombocytopenia and Isatuximab.(Sarclisa)For non-driver mutations in myeloma and mantle cell lymphoma, etc.

BMS: Up to 20Cut 2 billion US dollars cost at the end of 27 years

Lilly: The Birth of the First Super Blockbuster

Roche: Layout in Obesity Field Gradually Shows Results
Roche's best-performing products in the 2024 market are Ocrevus (ocrelizumab), Hemlibra (emicizumab), and Vabysmo (faricimab), with sales of 6.744 billion Swiss francs, 4.503 billion Swiss francs, and 3.864 billion Swiss francs, respectively. Among them, ocrelizumabIt is a multiple sclerosis drug that hasRanked No.1 for 4 consecutive years。
In 2025, Roche will have 7 indications receiving regulatory approvals, in addition to 19 key clinical data reads, includingGLP-1R/GIPR Dual Agonist CT-868(Once-daily subcutaneous injection) Phase II study data for the treatment of type 1 diabetes with obesity,Oral GLP-1R Agonist CT-996TreatmentPhase I Clinical Results of Type 2 Diabetes Mellitus with Obesity.

AstraZeneca: Revenue in China Hits Record High
On February 6 local time, AstraZeneca released its 2024 financial report for the full year.Revenue: $54.073 billion (+21%), including product sales of $50.938 billion (+19%).Revenue in China hit a record high, reaching $6.413 billion (+11%), accounting for 12% of total revenue.R&D investment of $13.583 billion, a year-on-year increase of 25%.For more details on AstraZeneca's 2024 financial report, seeClick the linkView。
GSK: Full-year revenue exceeds $40 billion, oncology drug sales double
In 2024,GlaxoSmithKline (GSK)Full-year revenue of 31.376 billion pounds (40.127 billion US dollars), an increase of 7% year-on-year.R&D investment of 6.401 billion pounds($8.186 billion), an increase of 5% year-on-year. More details about GSK's 2024 financial report are available.Click the linkView。
Novo Nordisk: "Semaglutide" Rakes in $293 Billion
2024 In the year, Novo Nordisk's global sales reached 290.4 billion Danish kroner, approximately $42.149 billion., increased by 26%。Among them,"Semaglutide" Sales Reach $29.296 Billion。Click the linkLearn more about Novo Nordisk's 2024 financial report.
Amgen: 21 Products Achieve Record-High Sales for the Year
On February 4 local time, Amgen announced its financial results, with total revenue for the full year 2024 increasing by 19% year-over-year to reach $33.4 billion, including Q4 total revenue rising 11% year-over-year to $9.1 billion. Excluding sales contributions from the acquisition of Horizon, revenue from other products grew by 7%, primarily driven by an 11% increase in sales volume.For more details on Amgen's 2024 financial report, seeClick the linkView。
Insight has collected 19 MNC 2024 Annual Report for Industry Reference,You can add Xiaoyin as a WeChat friend.Send "2024 Financial Report" to download.

Resource List

Cover Source:Zhan Kou Hai Luo
Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.
Editor: ccai/Crescent/Xin Yao
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……
Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock!
